Based on ratings from 9 stock analysts, the Array BioPharma Inc stock price is expected to increase by 100% in 12 months. This is calculated by using the average 12-month stock price forecast for Array BioPharma Inc. The lowest target is $7 and the highest is $22. Please note analyst price targets are not guaranteed and could be missed completely.
About 9 Wall Street analysts have assignedARRY 8 buy ratings, 1 hold ratings, and 0 sell ratings. This means that analysts expect Array BioPharma Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ARRY. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ARRY.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Colin Rusch Oppenheimer | Outperform | $14 | Maintains | Nov 8, 2024 |
Paul Coster JP Morgan | Overweight | $15 | Maintains | Nov 8, 2024 |
Philip Shen Roth MKM | Neutral | $6 | Maintains | Nov 8, 2024 |
Jon Windham UBS | Buy | $10 | Maintains | Nov 8, 2024 |
Joseph Osha Guggenheim | Neutral | Downgrade | Nov 7, 2024 | |
Kashy Harrison Piper Sandler | Neutral | $7 | Maintains | Oct 22, 2024 |
Paul Coster JP Morgan | Overweight | $20 | Maintains | Oct 17, 2024 |
Biju Perincheril Susquehanna | Positive | $10 | Maintains | Oct 16, 2024 |
Jordan Levy Truist Securities | Buy | $10 | Maintains | Oct 16, 2024 |
Ameet Thakkar BMO Capital | Market Perform | $9 | Maintains | Oct 14, 2024 |
Joseph Osha Guggenheim | Buy | $12 | Maintains | Oct 4, 2024 |
Christine Cho Barclays | Overweight | $10 | Maintains | Oct 3, 2024 |
Julien Dumoulin-Smith Jefferies | Buy | $11 | Upgrade | Sep 4, 2024 |
Tristan Richardson Scotiabank | Sector Outperform | $12 | Maintains | Aug 16, 2024 |
Joseph Osha Guggenheim | Buy | $14 | Maintains | Aug 16, 2024 |
Christine Cho Barclays | Overweight | $11 | Maintains | Aug 12, 2024 |
Jordan Levy Truist Securities | Buy | $12 | Maintains | Aug 12, 2024 |
Ameet Thakkar BMO Capital | Market Perform | $11 | Maintains | Aug 9, 2024 |
Colin Rusch Oppenheimer | Outperform | $17 | Maintains | Aug 9, 2024 |
Jon Windham UBS | Buy | $16 | Maintains | Aug 9, 2024 |
When did it IPO
2010
Staff Count
1,013
Country
United States
Sector/Industry
Technology/Solar
CEO
Mr. Kevin G. Hostetler
Market Cap
$917.7M
In 2023, ARRY generated $1.58B in revenue, which was a decrease of -3.72% from the previous year. This can be seen as a signal that ARRY's business is declining, and its share price could be worth less in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Array Technologies, Inc. will hold its Q3 2024 Earnings Conference Call on November 7, 2024, at 5:00 PM ET, featuring key executives and analysts from various financial institutions.
Why It Matters - The earnings call provides insight into Array Technologies' financial performance and future outlook, influencing investor sentiment and stock price movements.
Summary - ARRAY Technologies reported Q3 2024 revenue of $231.4M and a gross margin of 33.8%. Net loss was $155.4M, including a $162M goodwill impairment. Adjusted EBITDA was $46.7M.
Why It Matters - ARRAY Technologies reported a significant net loss largely due to a non-cash impairment charge, despite positive adjusted EBITDA and gross margins. This mixed performance could affect investor sentiment and stock valuation.
Summary - Array Technologies, Inc. (ARRY) reported Q3 earnings of $0.17 per share, exceeding the Zacks estimate of $0.14 but down from $0.21 per share year-over-year.
Why It Matters - Array Technologies' earnings beat expectations, indicating operational strength, but the year-over-year decline may raise concerns about future growth and profitability.
Summary - Trump may reverse green policies from the Biden administration, including solar tax credits and incentives from the Inflation Reduction Act, impacting investments in renewable energy.
Why It Matters - Changes in green policies could impact renewable energy investments, affecting market dynamics and stock performance in related sectors. Adjustments in tax credits may influence company valuations.
Summary - Recent nuclear energy news has positively impacted the solar energy sector, indicating a potential shift in market dynamics.
Why It Matters - Nuclear energy developments can shift market dynamics, potentially boosting solar investments as alternatives, impacting energy sector valuations and investor sentiment.
Summary - Array Technologies (ARRY) may struggle to meet earnings expectations in its upcoming report due to lacking key performance indicators. Investors should prepare for this potential outcome.
Why It Matters - Array Technologies may underperform in its upcoming earnings report, signaling potential volatility or decline in stock value, impacting investor confidence and strategies.